Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort.
VEXAS syndrome
azacytidine
myelodysplastic neoplasms (MDS)
next generating sequencing
ruxolitinib
vacuoles
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
11
12
2023
accepted:
08
01
2024
medline:
9
2
2024
pubmed:
9
2
2024
entrez:
9
2
2024
Statut:
epublish
Résumé
VEXAS syndrome is an acquired autoinflammatory disease characterized in most cases by cytopenias and macrocytic anemia. Dyshematopoiesis is a frequent finding in chronic inflammatory conditions and therefore, cytopenias are not easily classified in VEXAS patients. Here we report a series of 7 patients affected by VEXAS associated cytopenias, treated at our center. The use of NGS, together with morphological assays, integrated with the WHO 2022 criteria, allowed to identify three subsets of VEXAS associated cytopenias: ICUS (idiopathic cytopenia of uncertain significance), CCUS (clonal cytopenia of uncertain significance) at high risk of clonal evolution, and MDS. This approach could help to better understand the nature of VEXAS associated cytopenias and to guide the use of specific targeted treatments in order to achieve long lasting responses.
Identifiants
pubmed: 38333211
doi: 10.3389/fimmu.2024.1354130
pmc: PMC10850384
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1354130Informations de copyright
Copyright © 2024 Diral, Campochiaro, Tomelleri, Bergonzi, Pizzano, Ponzoni, Bongiovanni, Ronchi, Tresoldi, Rigamonti, Scarfò, Latino, Rinaldi, Bernardi, Dagna and Ciceri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.